A Phase 1 Study of NLG802 for Adult Patients With Recurrent Advanced Solid Tumors
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 23 May 2019
Price : $35 *
At a glance
- Drugs NLG 802 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors NewLink Genetics Corporation
- 23 May 2019 According to a NewLink Genetics Corporation media release, data from the study were presented at the Immuno-Oncology 2019 2nd World Congress.
- 23 May 2019 Results presented in a NewLink Genetics Corporation media release.
- 06 May 2019 According to a NewLink Genetics Corporation media release, data from this trial will be presented at Immuno-Oncology 2019 World Congress.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History